Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
09/26/2022 | 5.8% | Truist Securities | $64 → $61 | Maintains | Hold |
06/21/2022 | 7.54% | BMO Capital | → $62 | Downgrades | Outperform → Market Perform |
04/19/2022 | 5.8% | BMO Capital | $63 → $61 | Maintains | Outperform |
02/01/2022 | -11.54% | Credit Suisse | → $51 | Initiates Coverage On | → Underperform |
01/07/2022 | 17.94% | BMO Capital | → $68 | Upgrades | Market Perform → Outperform |
07/23/2021 | 24.88% | Wells Fargo | $74 → $72 | Maintains | Equal-Weight |
06/18/2021 | 23.15% | BMO Capital | → $71 | Upgrades | Underperform → Market Perform |
03/30/2021 | 33.55% | Capital One | → $77 | Downgrades | Overweight → Equal-Weight |
01/13/2021 | -4.6% | Mizuho | → $55 | Downgrades | Neutral → Underperform |
01/08/2021 | — | BMO Capital | Downgrades | Market Perform → Underperform | |
12/14/2020 | — | Keybanc | Upgrades | Underweight → Sector Weight | |
09/02/2020 | 9.27% | Stifel | → $63 | Reinstates | → Hold |
06/24/2020 | 11.01% | SunTrust Robinson Humphrey | $61 → $64 | Maintains | Hold |
06/17/2020 | 14.47% | Wells Fargo | $54 → $66 | Maintains | Equal-Weight |
06/08/2020 | — | JMP Securities | Reinstates | → Market Perform | |
05/22/2020 | -4.6% | Mizuho | $60 → $55 | Downgrades | Buy → Neutral |
05/14/2020 | -30.62% | Keybanc | $43 → $40 | Maintains | Underweight |
04/23/2020 | 5.8% | SunTrust Robinson Humphrey | $77 → $61 | Maintains | Hold |
04/21/2020 | -25.42% | Keybanc | $65 → $43 | Maintains | Underweight |
03/26/2020 | -11.54% | Wells Fargo | $82 → $51 | Maintains | Equal-Weight |
02/05/2020 | — | Berenberg | Initiates Coverage On | → Buy | |
01/07/2020 | 42.23% | BMO Capital | → $82 | Upgrades | Underperform → Market Perform |
12/20/2019 | 64.77% | Mizuho | → $95 | Assumes | → Buy |
02/20/2019 | — | BMO Capital | Downgrades | Market Perform → Underperform | |
08/08/2018 | 38.76% | Cantor Fitzgerald | $75 → $80 | Maintains | Neutral |
05/31/2018 | 30.08% | Wells Fargo | $68 → $75 | Maintains | Market Perform |
04/17/2018 | 4.07% | Keybanc | $70 → $60 | Maintains | Underweight |
12/19/2017 | — | Keybanc | Downgrades | Sector Weight → Underweight | |
10/23/2017 | — | Capital One | Initiates Coverage On | → Equal-Weight | |
10/11/2017 | 38.76% | SunTrust Robinson Humphrey | → $80 | Initiates Coverage On | → Hold |
National Health Investors Questions & Answers
The latest price target for National Health Investors (NYSE: NHI) was reported by Truist Securities on September 26, 2022. The analyst firm set a price target for $61.00 expecting NHI to rise to within 12 months (a possible 5.80% upside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for National Health Investors (NYSE: NHI) was provided by Truist Securities, and National Health Investors maintained their hold rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of National Health Investors, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for National Health Investors was filed on September 26, 2022 so you should expect the next rating to be made available sometime around September 26, 2023.
While ratings are subjective and will change, the latest National Health Investors (NHI) rating was a maintained with a price target of $64.00 to $61.00. The current price National Health Investors (NHI) is trading at is $57.66, which is out of the analyst's predicted range.